Status:
UNKNOWN
Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Eligibility:
All Genders
18-120 years
Brief Summary
Genetic mutations have closely linked to the pathogenesis and prognostication of myeloid cancers. In addition, a number of molecularly targeted agents have been developed in recent years. With the adv...
Detailed Description
Genetic mutations have closely linked to the pathogenesis and prognostication of myeloid cancers (including acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms). In rec...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients ≥ 18 years of age diagnosed with myeloid cancers (including acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms).
- Healthy Volunteers ≥ 18 years of age.
- Participants must be willing to provide voluntary written informed consent before study related procedures.
- Exclusion criteria:
- Patients ≥ 18 years of age diagnosed with non-myeloid cancers.
- Patients \<18 years of age diagnosed with myeloid cancers (including acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms).
Exclusion
Key Trial Info
Start Date :
August 19 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04060485
Start Date
August 19 2019
End Date
December 31 2024
Last Update
August 19 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100